In addition, the developed immunosensor was also employed to detect p-tau protein in healthy controls and AD patients’ plasma samples; further, it showed remarkable selectivity for both Aβ(1-42) (85.7%) and p-tau (70%). The gene discussed is MAPT; the disease is Alzheimer disease.